Trastuzumab, commercially known as Herceptin, is a Roche-developed HER2-targeted therapy that can directly treat HER2+ cancer cells, which are commonly overexpressed in breast and stomach cancer and have also been suggested to be present in esophageal cancer [74]. This evidence concerns the gene ERBB2 and esophageal cancer.